Hannah Blau, M.B.B.S, Joins AIT’s Scientific Advisory Board
REHOVOT, Israel, December 16, 2013 /PRNewswire/ –
Advanced Inhalation Therapies (AIT), a leader in the development of innovative
therapeutics for the treatment of infectious respiratory diseases, announced today the
appointment of Hannah Blau, M.B.B.S,to its scientific advisory board.
Prof. Hannah Blau holds the position of Director, Pulmonary institute & Chair of the
Graub Cystic Fibrosis Center, Schneider Children’s Medical Center of Israel, and is an
Associate Professor at Tel Aviv University.
“I am very pleased to welcome Dr. Hannah Blau to AIT’s SAB. Her tremendous expertise
and researches in the field of cystic fibrosis will greatly contribute to AIT in its
advanced studies. In the following months we will start a Phase II multi center study for
subjects with CF in our CF program and having Dr. Hannah Blau on board is a great honor
for us ” says David Greenberg M.D., Chief Medical Officer at AIT and a Professor of
Pediatrics and Infectious Diseases at the Soroka Medical Center in Beer Sheva, Israel.
Cystic fibrosis is an inherited chronic disease that affects the lungs and digestive
system of about 30,000 children and adults in the United States (70,000 worldwide). A
defective gene and its protein product cause the body to produce unusually thick, sticky
- Clogs the lungs and leads to life-threatening lung infections - Obstructs the pancreas - Stops natural enzymes from helping the body break down and absorb food.
“I am honored to join AIT’s scientific advisory board, said Dr. Blau.” CF is a life
threating disease that affects so many children and adults around the world. I believe
there is a great potential using formulation of Nitric Oxide to help and bring a new
solution for the airway infections, often with multi-resistant bacteria and fungi that
afflict CF patients. I am looking forward to working alongside AIT’s experienced
management team as they continue to advance the Company’s pipeline and forge new strategic
collaborations within the industry.”
AIT focuses on the development of unique nitric oxide formulations for the treatment
of respiratory infectious diseases, including human respiratory syncytial virus (RSV),
bronchiolitis, cystic fibrosis, pneumonia and asthma. The company is currently conducting
multi-center Phase II trials in children and adults with CF as well as a Phase II for
human respiratory syncytial virus (RSV) & bronchiolitis in infants. Mid-study results in
bronchiolitis (children Pneumonia) demonstrated the safety of AIT’s nitric oxide
formulation in children.
AIT (http://www.ait-pharm.com) is an Israeli biomed company focused on the
development and commercialization of formulations from nitric oxide for the treatment of
infectious diseases. The company was founded in 2011 by Mor Research Applications, a
subsidiary of Clalit Health Services, Israel’s largest health management organization.
The company is conducting Phase II trials on bronchiolitis after successful completion
of Phase I trials. AIT develops products for the treatment of bronchiolitis, pneumonia,
cystic fibrosis and asthma.
About Clalit Health Services
Schneider Children’s Medical Center is a member of Clalit Health Services, the largest
HMO in Israel, and one of the most progressive public health associations in the world.
Through its 14 hospitals and more than 1,400 primary and specialized clinics, Clalit
provides comprehensive health insurance and highly advanced medical care to the majority
of Israel’s population. It is also the only health fund with a countrywide network of 425
state-of-the-art pharmacies, 70 dental clinics, 80 clinical laboratories, 35 separate
radiology facilities, as well as computerized diagnostic equipment at a number of central
Clalit has 4 million insured members in Israel (>52% market share).
Clalit is the only health organization that has an extensive network of hospitals
throughout the country. Clalit maintains a total of 14 general and special care hospitals
which are all university affiliate
In the long-term interest of the entire population, Clalit conducts clinical,
biomedical, and social science research in its own facilities, or in cooperation with
Israel’s universities and scientific institutions.
Contact information Racheli Vizman, COO, AIT 2 Derech Meir Weisgal Rehovot 9632605, Israel E-mail: email@example.com Direct: +972-8-684-3313 Mobile: +972-52-565-9922
SOURCE Advanced Inhalation Therapies (AIT)